CHG-2023-0162
Facility Change for Respiralimab. Formulation Change for Respiralimab — major revision. Impacts 7 markets and 2 variations.
Change Number
CHG-2023-0162
Type
Facility Change
Product
Status
Approved
Owner
Priya Sharma
Initiated
2022-07-21
Description
Formulation Change for Respiralimab — major revision
Impacted Markets (7)
BR — BrazilGB — United KingdomFR — FranceIT — ItalyMX — MexicoZA — South AfricaAT — Austria
Impacted Modules
3.2.S3.2.P3.2.P.3
Linked Variations (0)
| Variation # | Type | Application | Status | Submitted | Approved |
|---|